When it comes to Alzheimers versus science, science is on the losing side.
Alzheimers is cruel in the most insidious way. The disorder creeps up in some aging brains, gradually eating away at their ability to think and reason, whittling down their grasp on memories and reality. As the worlds population ages, Alzheimers is rearing its ugly head at a shocking rate. And despite decades of research, we have no treatmentnot to mention a cure.
Too much of a downer? The National Institutes of Health (NIH) agrees. In one of the most ambitious projects in biology, the NIH is corralling Alzheimers and stem cell researchers to come together in the largest genome editing project ever conceived.
The idea is simple: decades of research have found certain genes that seem to increase the chance of Alzheimers and other dementias. The numbers range over hundreds. Figuring out how each connects or influences anotherif at alltakes years of research in individual labs. What if scientists unite, tap into a shared resource, and collectively solve the case of why Alzheimers occurs in the first place?
The initiatives secret weapon is induced pluripotent stem cells, or iPSCs. Similar to most stem cells, they have the ability to transform into anythinga cellular Genie, if you will. iPSCs are reborn from regular adult cells, such as skin cells. When transformed into a brain cell, however, they carry the original genes of their donor, meaning that they harbor the original persons genetic legacyfor example, his or her chance of developing Alzheimers in the first place. What if we introduce Alzheimers-related genes into these reborn stem cells, and watch how they behave?
By studying these iPSCs, we might be able to follow clues that lead to the genetic causes of Alzheimers and other dementiaspaving the road for gene therapies to nip them in the bud.
The iPSC Neurodegenerative Disease Initiative (iNDI) is set to do just that. The project aims to stimulate, accelerate, and support research that will lead to the development of improved treatments and preventions for these diseases, the NIH said. All resulting datasets will be openly shared online, for anyone to mine and interpret.
In plain language? Lets throw all of our new biotech superstarswith CRISPR at the forefrontinto a concerted effort against Alzheimers, to finally gain the upper hand. Its an Avengers, assemble moment towards one of our toughest foesone that seeks to destroy our own minds from within.
Alzheimers disease was first recognized in the early 1900s. Ever since, scientists have strived to find the cause that makes a brain waste away.
The most prominent idea today is the amyloid hypothesis. Imagine a horror movie inside a haunted house with ghosts that gradually intensify in their haunting. Thats the amyloid horrora protein that gradually but silently builds up inside a neuron, the house, eventually stripping it of its normal function and leading to the death of anything inside. Subsequent studies also found other toxic proteins that hang around outside the neuron house that gradually poison the molecular tenants within.
For decades scientists have thought that the best approach to beat these ghosts was an exorcismthat is, to get rid of these toxic proteins. Yet in trial after trial, they failed. The failure rate for Alzheimers treatmentso far, 100 percenthas led some to call treatment efforts a graveyard of dreams.
Its pretty obvious we need new ideas.
A few years ago, two hotshots strolled into town. One is CRISPR, the wunderkind genetic sharpshooter that can snip way, insert, or swap out a gene or two (or more). The other is iPSCs, induced pluripotent stem cells, which are reborn from adult cells through a chemical bath.
The two together can emulate Dementia 2.0 in a dish.
For example, using CRISPR, scientists can easily insert genes related to Alzheimers, or its protection, into an iPSCeither that from a healthy donor, or someone with a high risk of dementia, and observe what happens. A brain cell is like a humming metropolitan area, with proteins and other molecules whizzing around. Adding in a dose of pro-Alzheimers genes, for example, could block up traffic with gunk, leading scientists to figure out how those genes fit into the larger Alzheimers picture. For the movie buffs out there, its like adding into a cell a gene for Godzilla and another for King Kong. You know both could mess things up, but only by watching what happens in a cell can you know for sure.
Individual labs have tried the approach since iPSCs were invented, but theres a problem. Because iPSCs inherit the genetic baseline of a person, it makes it really difficult for scientists in different labs to evaluate whether a gene is causing Alzheimers, or if it was just a fluke because of the donors particular genetic makeup.
The new iNDI plan looks to standardize everything. Using CRISPR, theyll add in more than 100 genes linked to Alzheimers and related dementias into iPSCs from a wide variety of ethnically diverse healthy donors. The result is a huge genome engineering project, leading to an entire library of cloned cells that carry mutations that could lead to Alzheimers.
In other words, rather than studying cells from people with Alzheimers, lets try to give normal, healthy brain cells Alzheimers by injecting them with genes that could contribute to the disorder. If you view genes as software code, then its possible to insert code that potentially drives Alzheimers into those cells through gene editing. Execute the program, and youll be able to observe how the neurons behave.
The project comes in two phases. The first focuses on mass-engineering cells edited with CRISPR. The second is thoroughly analyzing these resulting cells: for example, their genetics, how their genes activate, what sorts of proteins they carry, how those proteins interact, and so on.
By engineering disease-causing mutations in a set of well-characterized, genetically diverse iPSCs, the project is designed to ensure reproducibility of data across laboratories and to explore the effect of natural variation in dementia, said Dr. Bill Skarnes, director of cellular engineering at the Jackson Laboratory, and a leader of the project.
iNDI is the kind of initiative thats only possible with our recent biotech boost. Engineering hundreds of cells related to Alzheimersand to share with scientists globallywas a pipe dream just two decades ago.
To be clear, the project doesnt just generate individual cells. It uses CRISPR to make cell lines, or entire lineages of cells with the Alzheimers gene that can pass on to the next generation. And thats their power: they can be shared with labs around the world, to further hone in on genes that could make the largest impact on the disorder. Phase two of iNDI is even more powerful, in that it digs into the inner workings of these cells to generate a cheat codea sheet of how their genes and proteins behave.
Together, the project does the hard work of building a universe of Alzheimers-related cells, each outfitted with a gene that could make an impact on dementia. These types of integrative analyses are likely to lead to interesting and actionable discoveries that no one approach would be able to learn in isolation, the authors wrote. It provides the best chance at truly understanding Alzheimers and related diseases, and promising treatment possibilities.
Image Credit: Gerd Altmann from Pixabay
Here is the original post:
- New Cell Therapy Shows Promise in Treating HIV - BioSpace - May 14th, 2021
- The Worldwide Stem Cell Therapy Industry is Projected to Reach $401 Million by 2026 at a CAGR of 16.5% from 2021 - PRNewswire - May 14th, 2021
- Global Stem Cell Reconstructive Market 2021 Top Players Osiris Therapeutics, NuVasive, Cytori Therapeutics, Takeda (TiGenix), Cynata, Celyad,... - May 14th, 2021
- ONLINE: The Future of Heart Care - Isthmus - May 14th, 2021
- Rinri Therapeutics Secures Innovate UK Funding Grant for 3.2m Project to Advance its Novel Cell-Based Therapy to Restore Hearing Loss - PRNewswire - May 14th, 2021
- Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs... - May 14th, 2021
- Cytovia Therapeutics Expands Leadership Team - GlobeNewswire - May 14th, 2021
- Stem Cell and Regenerative Therapy Market COVID-19 impact analysis, segmentation, key players, opportunities and forecast 2020 - 2026 - WhaTech - May 14th, 2021
- Comprehensive Atlas of Reef-Building Corals Cells Created - The Scientist - May 14th, 2021
- Fascination with stem cell sensation leads to Fulbright scholarship - Monash University - May 12th, 2021
- The Competitive Zeal To Decide The Dimensions Of Growth Of The Induced Pluripotent Stem Cells Market The Courier - The Courier - May 12th, 2021
- Gene therapy offers potential cure to children born without an immune system - UCLA Newsroom - May 12th, 2021
- With $52 Million Series A, Appia Bio Anticipates a Bright Future in Cell Therapy - BioSpace - May 12th, 2021
- Advanced Therapy Medicinal Products Market Size Worth $21.2 Billion By 2028: Grand View Research, Inc. - PRNewswire - May 12th, 2021
- The Univer-cell Alchemist: Dr Subhadra Dravidas breakthrough research on novel stem cell treatment for Covid patients - The New Indian Express - May 10th, 2021
- Stem Cell Therapy Market 2021-2026: Industry Analysis, Geographical Segmentation, Drivers, Challenges, and Trend & Forecasts KSU | The Sentinel... - May 9th, 2021
- Hope, hype and exploitation the wild history of stem cell science - ABC News - May 2nd, 2021
- Scientists create first-of-its-kind 3D organoid model of the human pancreas - Newswise - May 2nd, 2021
- Researchers map the first complete atlas of single cells that make up the human teeth - News-Medical.net - April 30th, 2021
- Researchers develop first 3D organoid models of the pancreas from human stem cells - News-Medical.net - April 30th, 2021
- The first comprehensive single-cell atlas of human teeth - Newswise - April 30th, 2021
- Revotek Deploys Its Bioink Technology to Research Institutes - PRNewswire - April 30th, 2021
- Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy -... - April 30th, 2021
- Controversial experiment with human cells growing in monkey embryos | Science and Health - SwordsToday.ie - April 30th, 2021
- Adipose Tissue-Derived Stem Cells (ADSCS) Market Value with Volume and Growth Prospects 2021 to 2027 The Courier - The Courier - April 30th, 2021
- Placental-derived stem cell therapy shows promise to heal intestinal disease in premature babies - News-Medical.Net - April 28th, 2021
- Tissue Regeneration Market: Stem Cell Therapy to be Highly Attractive Segment - BioSpace - April 28th, 2021
- Repairing stroke and Alzheimer's disease damage with stem cell therapy - Health Europa - April 28th, 2021
- Stem Cell Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030 - Yahoo Finance - April 28th, 2021
- Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting - PRNewswire - April 28th, 2021
- Vitro Biopharma Inc. January 31st 2021, 1st Quarter ended Financial Results of Operations and Shareholder Letter - Benzinga - April 28th, 2021
- Longeveron Selected to Present at the 2021 World Stem Cell Summit - GlobeNewswire - April 28th, 2021
- Prostate organoid technology - the new POT of gold in prostate stem cell and cancer research - DocWire News - April 28th, 2021
- University of Illinois Urbana-Champaign and Mayo Clinic Researchers Develop New Technique to Study 'Microcancers' and Screen Cancer-Fighting Drugs -... - April 28th, 2021
- Research with fetal tissue from elective abortion called 'deeply offensive' - Catholic San Francisco - April 28th, 2021
- Integration of Cellular Therapy Jumpstarts Research Efforts in Acute Leukemias - OncLive - April 28th, 2021
- Stem Cell Therapy for Diabetes and Related Conditions Market 2021 Competitive Insights Sanofi, Novo Nordisk, Mesoblast, Caladrius Biosciences,... - April 26th, 2021
- This technology was designed to grow human cells. Now it's transforming the cultured meat industry. - Massive Science - April 26th, 2021
- Global Canine Stem Cell Therapy Market is Projected to Grow at a CAGR of 9.3% during (2018 2026) NeighborWebSJ - NeighborWebSJ - April 26th, 2021
- Top Key-Players To Be Restored To The First Position In The Recombinant Cell Culture Supplements Market The Courier - The Courier - April 26th, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Global Market Report (2020-2027) Segmented by Type, Application and region (NA, EU, and etc.) The... - April 26th, 2021
- Three-dimensional microscale hanging drop arrays with geometric control for drug screening and live tissue imaging - Science Advances - April 24th, 2021
- Stem Cell Banking Market: Rise in Incidence of Chronic Conditions to Drive the Market - BioSpace - April 24th, 2021
- How Brown neuroscientists are using CRISPR to accelerate brain research and more - Brown University - April 24th, 2021
- Biotechnology in BCfuture treatments and potential cures for cancer - UBC Faculty of Medicine - UBC Faculty of Medicine - April 24th, 2021
- Scientists have moved closer to making organisms that are part human and part animal - Scroll.in - April 24th, 2021
- Impact of COVID-19 on Stem Cell Therapy Market is Booming Worldwide with Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene,... - April 24th, 2021
- Single-Use Bioreactors Market by Type of Reactor, Scale of Operation, Cell Culture System, Type of Molecule, Application Area, Purpose, End-User, and... - April 24th, 2021
- Stem cell therapy promotes recovery from stroke and dementia in mice - UCLA Newsroom - April 22nd, 2021
- Accelerating Cures Through Research - New York Stem Cell ... - April 22nd, 2021
- Stem cell therapy can repair brain damage and improve memory function in mice - News-Medical.Net - April 22nd, 2021
- 'Re-imagining' mice and men - The Highland County Press - April 22nd, 2021
- Research with fetal tissue from elective abortion called 'deeply offensive' - The Catholic Sun - April 22nd, 2021
- Research with fetal tissue from abortion called 'deeply offensive' - CatholicPhilly.com - April 22nd, 2021
- Do our brains age faster than the rest of our bodies? - ScienceBlog.com - April 22nd, 2021
- Study discovers mechanism involved in the development of metaplasia in the esophagus - News-Medical.Net - April 22nd, 2021
- Research Reveals Distinct Types of Cells That May Be Involved in Breathing-Related Diseases in Infants - Technology Networks - April 22nd, 2021
- Breakthrough Paper Outlines Path to Heart Regeneration After Cardiac Injury - PR Web - April 22nd, 2021
- Stem Cells Market to Witness Robust Expansion Throughout the Forecast Period 2018-2026 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - April 20th, 2021
- Animal Stem Cell Therapy Market Study Report and In-deep Analysis 2020 2026 The Courier - The Courier - April 20th, 2021
- Global Cord Blood Stem Cells Market to 2026 Industry Perspective, Comprehensive Analysis, and Forecast KSU | The Sentinel Newspaper - KSU | The... - April 20th, 2021
- Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell... - April 18th, 2021
- StemSynergy Therapeutics' Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells - Business Wire - April 16th, 2021
- US researchers create the first human-monkey chimaera, in the midst of a raging debate on such experimentation - The Financial Express - April 16th, 2021
- CAR T-Cell Therapy Enters the Arena in Multiple Myeloma With Ongoing Research Ahead - OncLive - April 16th, 2021
- Treating chronic myeloid leukemia (CML): By phase and more - Medical News Today - April 16th, 2021
- Cellino Biotech developing tech to help scale stem cell therapies - MedCity News - April 14th, 2021
- Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021: Methods of Commercializing iPSCs are Diverse and Continue to Expand -... - April 14th, 2021
- eQcell Inc Announces the Appointment of Members of the Board of Directors - BioSpace - April 14th, 2021
- Researchers Receive Grant to Improve Cellular Therapies to Treat 'Incurable' Diseases - University of Arkansas Newswire - April 14th, 2021
- Lonza Celebrates 20th Anniversary of Nucleofector Cell Transfection Platform - Technology Networks - April 14th, 2021
- New consortium aims to accelerate development of stem cell-based therapies for Huntingtons disease - News-Medical.Net - April 10th, 2021
- Strengthening the Stem Cell Industry Through Better Regulation - The Regulatory Review - April 10th, 2021
- Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021: Research, Patents, Funding Events, Industry Partnerships, Biomedical... - April 10th, 2021
- Stem Cell Transplantation May Be Offered Less Often as a Treatment Option for Some Patients with Mantle Cell Lymphoma - Curetoday.com - April 10th, 2021
- Real-time imaging shines light on the coordination of neural stem cell activation - News-Medical.net - April 10th, 2021
- Searching for Molecular Targets in Myeloid Malignancies and Beyond - OncLive - April 10th, 2021
- Fitore Nutrition Launches Spectrum + to Better the Lives of Children With Autism - Influencive - April 10th, 2021
- Cancer Stem Cells Market By Size Estimation, Growth Rate, Regional Analysis With with the CAGR of 11.0% Over the Forecast Period. KSU | The Sentinel... - April 10th, 2021
- global market for regenerative medicines is predicted to grow at a CAGR of 13.99% over the forecast period of 2020-2030 - GlobeNewswire - April 10th, 2021